Escient Pharmaceuticals

Acquired

San Diego, United States · Founded 2018

Employees
51–200
Founded
2018
Business Model
B2B
Last Round
Series CNov 2022
Rounds
3
Acquired by
IncyteApr 2024

About

Escient Pharmaceuticals was a San Diego-based clinical-stage biopharmaceutical company focused on developing oral small molecule therapeutics for mast cell-mediated disorders including chronic urticaria, cholestatic pruritus, and atopic dermatitis. Its lead program EP262 targeted MRGPRX2 receptors. Escient was acquired by Incyte Corporation for $750 million in 2024.

Summary

Escient Pharmaceuticals is a Pharmaceutical company based in San Diego, United States, founded in 2018. Its most recent funding was a Series C round in Nov 2022. Investors include NEA, Incyte and Abingworth Bioventures.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

AcquisitionApr 2024

Sign up to see all 4 rounds

Series A through Acquisition — per-round amounts, valuations, and who invested in each round.

Investors

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Escient Pharmaceuticals on Indexed.vc
<a href="https://indexed.vc/companies/escient-pharmaceuticals"><img src="https://indexed.vc/api/badge/company/escient-pharmaceuticals" alt="Escient Pharmaceuticals on Indexed.vc" width="260" height="76" /></a>